Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): Novel global treatment response model and outcomes in patients with alpha-mannosidosis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. European expert consensus statement on therapeutic goals in Fabry disease

    Research output: Contribution to journalReviewResearchpeer-review

  2. Exercising with blocked muscle glycogenolysis: Adaptation in the McArdle mouse

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Impaired glycogen breakdown and synthesis in phosphoglucomutase 1 deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Development of hypomelanotic macules is associated with constitutive activated mTORC1 in tuberous sclerosis complex

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. The challenges of managing coexistent disorders with phenylketonuria: 30 cases

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Impaired Fat Oxidation During Exercise in Long-Chain Acyl-CoA Dehydrogenase Deficiency Patients and Effect of IV-Glucose

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. l-Carnitine Improves Skeletal Muscle Fat Oxidation in Primary Carnitine Deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Osteogenesis imperfecta and the teeth, eyes, and ears-a study of non-skeletal phenotypes in adults

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Paul Harmatz
  • Federica Cattaneo
  • Diego Ardigò
  • Silvia Geraci
  • Julia B Hennermann
  • Nathalie Guffon
  • Allan Lund
  • Christian J Hendriksz
  • Line Borgwardt
View graph of relations

Alpha-mannosidosis is an ultra-rare monogenic disorder resulting from a deficiency in the lysosomal enzyme alpha-mannosidase, with a prevalence estimated to be as low as 1:1,000,000 live births. The resulting accumulation of mannose-rich oligosaccharides in all tissues leads to a very heterogeneous disorder with a continuum of clinical manifestations with no distinctive phenotypes. Long-term enzyme replacement therapy (ERT) with velmanase alfa is approved in Europe for the treatment of non-neurological manifestations in patients with mild to moderate alpha-mannosidosis. The clinical heterogeneity and rarity of the disease limit the sensitivity of single parameters to detect clinically relevant treatment effects. Thus, we propose a novel multiple variable responder analysis to evaluate the efficacy of ERT for alpha-mannosidosis and present efficacy analyses for velmanase alfa using this method. Global treatment response to velmanase alfa (defined by response to ≥2 domains comprising pharmacodynamic, functional, and quality of life outcomes) was applied post hoc to data from the pivotal placebo-controlled rhLAMAN-05 study and to the longer-term integrated data from all patients in the clinical development program (rhLAMAN-10). After 12 months of treatment, a global treatment response was achieved by 87% of patients receiving velmanase alfa (n = 15) compared with 30% of patients receiving placebo (n = 10). Longer-term data from all patients in the clinical program (n = 33) showed 88% of patients were global responders, including all (100%) pediatric patients (n = 19) and the majority (71%) of adult patients (n = 14). The responder analysis model demonstrates a clinically meaningful treatment effect with velmanase alfa and supports the early initiation and continued benefit of longer-term treatment of all patients with alpha-mannosidosis with this ERT.

Original languageEnglish
JournalMolecular Genetics and Metabolism
Volume124
Issue number2
Pages (from-to)152-160
Number of pages9
ISSN1096-7192
DOIs
Publication statusPublished - Jun 2018

ID: 56312021